Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) insider Arturo Md Molina sold 9,514 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total transaction of $784,714.72. Following the sale, the insider directly owned 97,266 shares in the company, valued at approximately $8,022,499.68. This trade represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Protagonist Therapeutics Price Performance

Shares of PTGX traded up $0.47 during trading hours on Wednesday, hitting $83.89. The company’s stock had a trading volume of 1,086,072 shares, compared to its average volume of 945,052. The business has a 50 day simple moving average of $86.58 and a two-hundred day simple moving average of $71.29. Protagonist Therapeutics, Inc. has a 52-week low of $33.70 and a 52-week high of $96.54. The company has a market cap of $5.24 billion, a price-to-earnings ratio of 135.31 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.03). The business had revenue of $4.71 million during the quarter, compared to the consensus estimate of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new stake in Protagonist Therapeutics during the 2nd quarter valued at about $27,000. Bessemer Group Inc. boosted its stake in shares of Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after purchasing an additional 318 shares during the period. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics in the third quarter worth approximately $29,000. CWM LLC boosted its position in Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after buying an additional 407 shares during the period. Finally, EverSource Wealth Advisors LLC grew its holdings in Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, October 13th. Weiss Ratings upgraded shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, December 24th. Citigroup boosted their price objective on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, December 8th. BTIG Research reiterated a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Finally, Truist Financial boosted their price target on shares of Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $86.77.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.